Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis

G Curigliano, V Mueller,V Borges,E Hamilton,S Hurvitz,S Loi,R Murthy,A Okines,E Paplomata,D Cameron,L A Carey,K Gelmon,G N Hortobagyi,I Krop,S Loibl,M Pegram,D Slamon,J Ramos,W Feng,E Winer

Annals of Oncology（2022）

引用 71|浏览13

暂无评分

摘要

•Tucatinib combination shows continued prolongation of overall survival in patients with HER2+ metastatic breast cancer.•Overall survival benefit was consistent across all prespecified subgroups, including patients with brain metastases.•The tucatinib combination was well tolerated with a low rate of discontinuation due to adverse events (5.9%).

查看译文

关键词

metastatic breast cancer,human epidermal growth factor receptor 2-positive (HER2),brain metastases,tucatinib,trastuzumab,capecitabine

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要